In colorectal cancer, SIRT3 silencing not only reduces the antioxidant capacity of the cell by regulating MnSOD acetylation and increases cell death to enhance the effect of oxaliplatin but also regulates mitochondrial function under oxidative conditions through PGC-1α, thereby decreasing the chemoresistance to the colorectal cancer cells (103, 104). Here, PPARGC1A is linked to colorectal cancer.